Hints and tips:
...SoftBank-backed construction startup (The Information) T-Mobile runs behind-the-scenes PR push to support Sprint deal (Reuters) BT investors call on next boss to consider break-up of business (FT) China Biologic...
...AstraZeneca drug improves overall survival for those with non-small cell lung cancer that has spread elsewhere in the body will not now be released until the second half of the year, the company and its global biologics...
...The Anglo-Swedish drugmaker, and MedImmune, its global biologics research and development arm, announced that the US Food and Drug Administration (FDA) had accepted the licence application for moxetumomab...
...AstraZeneca and MedImmune, its global biologics and development arm, hailed the US regulator’s decision to grant breakthrough status, which is awarded to medicines that fill a currently unmet medical need...
...French drugmaker Sanofi has poached the head of research at AstraZeneca’s biologics research and development arm, MedImmune, to lead its own global research and development....
...Amgen, founded in 1980, is one of the four cornerstone groups of the US biotech sector, along with Celgene, Gilead and Biogen, and is credited with developing some of the first successful “biologic” drugs...
...MedImmune gives it a capability in fast-growing biologics, which is less exposed to generic competition due to its scientific complexity....
...The deal also provides it with a position in the fast-expanding market for vaccines, and with potential spin-offs more generally in biologic medicines....
International Edition